Aceragen Inc News - ACGN | ADVFN

Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.

Get Started

Aceragen Inc (ACGN)

0.38

0.00

(0.00%)

Closed December 22 4:00PM

Delayed by 15 minutes

0.00

0.00

(0.00%)

After Hours: -

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form EFFECT - Notice of Effectiveness

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form POS AM - Post-Effective amendments for registration statement

Form POS AM - Post-Effective amendments for registration statement

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form POS AM - Post-Effective amendments for registration statement

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments

Form POS AM - Post-Effective amendments for registration statement

1
2
Next

Monksdream

Monksdream 1 year ago

ACGN new 52 week low

AJ Freely

AJ Freely 1 year ago

$ACGN - 🚀Up 7.3% Pre-Market/ Current Price $0.54
Delisting from The Nasdaq Stock Market
and appears to be being removed from ALL Markets permanently.

Monksdream

Monksdream 1 year ago

ACGN new 52 week low

Wesley Smith

Wesley Smith 2 years ago

Price to tangible book is .20 I've never seen this before Do your own DD

81vette

81vette 2 years ago

$50 million,partnership with Department of Defense’s,Defense Threat Reduction Agency (“DTRA”) to investigate ACG-701 as a potential medical countermeasure for melioidosis, a life-threatening infection caused by the B. pseudomallei pathogen. This program is centered around a Phase 2 trial, the TERRA study (NCT05105035), which is a randomized double-blind, placebo-controlled trial conducted in hospitalized melioidosis patients.

81vette

81vette 2 years ago

2.62M float,3.66M o/s,short .02M,book pps $3.23,cash/share $1.25,target $17.00,sales $4.86M,26 employees,insiders 8.6%,institutions 5.6%,volitility 16%-23%,shares available to short dropped 500% this morning,(still 1000 since 8am) <great sign of rebound,could go to ZERO BORROW soon,above ave buying vol.,accumulation started fri.

Delayed Upgrade Clock